Fig. 8: Tamsulosin, metoprolol, or bromocriptine monotherapies are not effective in improving retinal function in Rpe65−/− mice. | Nature Communications

Fig. 8: Tamsulosin, metoprolol, or bromocriptine monotherapies are not effective in improving retinal function in Rpe65−/− mice.

From: A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models

Fig. 8

Treatments were started at P21, and treatment effect was tested after 3–4 weeks of drug therapy. The drug effect was evaluated using two different methods: Scotopic ERG b-wave and optomotor response. The same vehicle-group data are used for comparison with each of the data sets for all treatments. Data in M is duplicated from Fig. 6J. A, B Tamsulosin (T) monotherapy data. C, D Metoprolol (M) monotherapy data. E, F Bromocriptine (B) monotherapy data. G, H Tamsulosin and bromocriptine (TB) dual-treatment data. I, J Tamsulosin and metoprolol (TM) dual-treatment data. K, L Metoprolol and bromocriptine (MB) dual-treatment data. M, N Tamsulosin, metoprolol, and bromocriptine (TMB) triple-treatment data. Statistical analysis for all data was performed using repeated measures two-ANOVA with the Geisser-Greenhouse correction followed by Bonferroni posthoc tests: *P < 0.05, **P < 0.01, ****P < 0.0001. Pound signs denote ANOVA between subject main effect significance levels: ##P < 0.01, ###P < 0.001, ####P < 0.0001. Data are presented as mean ± SD. Source data are provided as a Source Data file.

Back to article page